# Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer

> **NCT01010854** · PHASE2 · TERMINATED · sponsor: **University of California, San Francisco** · enrollment: 6 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** VPA FEC100

## Key facts

- **NCT ID:** NCT01010854
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12-10
- **Primary completion:** 2010-12-12
- **Final completion:** 2011-07-29
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Premature closure for lack of efficacy.
- **Last updated:** 2018-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01010854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01010854, "Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01010854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*